<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01709695</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 09-1825</org_study_id>
    <secondary_id>HSM:10-00415</secondary_id>
    <nct_id>NCT01709695</nct_id>
  </id_info>
  <brief_title>Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD</brief_title>
  <official_title>Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD): an Functional Magnetic Resonance Imaging(fMRI) Study of Brain Activation Pre and Post Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes to evaluate the effects of guanfacine extended release on brain
      activation during fMRI in children and adolescents with ADHD between the ages 8-15 and ADHD
      subjects randomized to placebo treatment.

      This study also proposes to collect DNA on study participants, to examine the genetic
      underpinning of the observed fMRI activation profiles at baseline and in response to
      treatment. The purpose is to examine polymorphisms of the adrenergic 2A gene (and other
      related targets) for genetic biomarkers in association with the fMRI findings of this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposes to evaluate the effects of guanfacine on brain activation during fMRI in
      12 children and adolescents ages 8 - 15 with ADHD treated with once-daily INTUNIV(TM)
      (guanfacine; GXR) extended release tablets and 12 ADHD subjects randomized to placebo
      treatment. Children will be comprehensively assessed using a variety of clinical and
      neuropsychological measures. They will be scanned at baseline while performing both the
      go/no-go task (a well validated task for measuring inhibitory control (Durston et al., 2002,
      2003)) and the Stay Alert task - a new task designed to measure the arousal component of
      attention, which was used successfully in a recent fMRI study of guanfacine in healthy adults
      (Clerkin et al., 2009). They will then be treated with GXR or placebo for 6 - 8 weeks in
      accordance with titration and dosing strategies used in recent Phase III dose optimization
      trials (e.g., up to 4 mg/day), and re-scanned while performing the same two tasks. The fMRI
      scans will be conducted using a dedicated research 3.0 T Siemens scanner.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Go/No-go Task Performance Correct Inhibitions</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Go/No-go Task Reaction Time</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Go/No-go Task Performance Correct Responses</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions (CGI-I)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Clinical response was the Clinical Global Impression-Improvement scale (CGI-I). Lower CGI-I scores indicate greater improvement (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Atomoxetine Stimulant Side Effects Rating Scale (ASSERS)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Side effects rating scale. Assesses side effects known to occur in prior research using stimulant and non stimulant medications for treatment of ADHD. Scores range from 0 (not present) to 9 (severe side effects) and have been reported in aggregate as sum of severity responses on highest dose. This number is the sum of ASSERS, meaning it is the number and severity of side effects experienced. The percentage change in score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Finger Windows</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological assessment: Finger Windows - a measure of spatial working memory. The participant shows memory of a demonstrated visual pattern. The examiner models a given sequence of windows and ask the participant to imitate the sequence by placing their finger through the same windows in the correct order. The total number of correct sequences achieved determines the level of performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological assessment - Digit Span. The Digit Span test is either conducted verbally or using a computer program. A sequence of numbers is shown or read out to the participant. The participant is then told to repeat the numbers that were shown or read to them. This process continues until the participant can no longer remember either the full sequence of numbers or the correct order. This sequence is also continued until the participant makes an error. The Digit Span test is scored by the amount of numbers the participant was able to remember in each test. The scorer must add the total number of correct sequences, backwards and forwards. This test is also scored differently for a range of ages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention Deficit Hyperactivity Disorder Rating Scale IV (ADHDRS IV)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Norm referenced parent interview to assess severity and frequency of ADHD symptoms. Scores are reported as sums 0 (no symptoms) to 54 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Performance Test - Commissions</measure>
    <time_frame>Baseline</time_frame>
    <description>Neuropsychological assessment - Continuous Performance Test - Commissions. CPT is a task-oriented computerized assessment of attention-related problems. Scores are compared with the normative scores for the age, group and gender of the person being tested. A t-score of 50 is equal to the mean, with higher values indicating more problematic behaviors and lower scores indicating less problematic behaviors.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>ADHD</condition>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>guanfacine hydrochloride XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Flexible dose titration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine Hydrochloride XR</intervention_name>
    <description>Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose</description>
    <arm_group_label>guanfacine hydrochloride XR</arm_group_label>
    <other_name>INTUNIV non-stimulant medication</other_name>
    <other_name>GXR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of any subtype of ADHD

          -  Normal findings on physical exam, laboratory studies, vital signs, and ECG

          -  Weight = 60 kgs or less

          -  Able to complete study procedures and swallow capsules;

          -  Willing to commit to the entire visit schedule

          -  Off treatment or have been discontinued from their previous medication for two weeks.

        Exclusion Criteria:

          -  Psychiatric comorbidity except Oppositional Defiant Disorder [ODD], Simple Phobia, and
             dysthymia (unless ongoing medication treatment is required);

          -  Currently a suicide risk, has previously made a suicide attempt or has a prior history
             of suicidal behavior;

          -  Has failed treatment with an adequate trial of an alpha-2 adrenergic agonist;

          -  Known or suspected allergy, hypersensitivity, or clinically significant intolerance to
             guanfacine hydrochloride.

        Children may not:

          -  be treated with systemic medication for a medical or psychiatric illness that have CNS
             effects or affect cognitive function;

          -  have a known history or presence of structural cardiac abnormalities, exercise-related
             cardiac events, or clinically significant bradycardia;

          -  have orthostatic hypotension or a known history of hypertension;

          -  have an abnormal ECG that is deemed clinically significant;

          -  have a history of alcohol or other substance abuse or dependence within the last 6
             months;

          -  use any medications that affect BP or heart rate (excluding the subject's current ADHD
             medication at screening);

          -  use another investigational medicinal product or participation in a clinical study
             within 30 days prior to the baseline visit;

          -  be significantly overweight based on Center for Disease Control and Prevention Body
             Mass Index (BMI)-for-age gender specific charts;

          -  have body weight of less than 25kg;

          -  have a clinically important abnormality on urine drug and alcohol screen (excluding
             the subject's current ADHD stimulant, if applicable);

          -  be female and currently pregnant or lactating;

          -  have symptoms indicative of a primary sleep disorder.

          -  have braces or other metal permanently placed within their body.

          -  be too anxious to tolerate the fMRI procedure, or be claustrophobic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Newcorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bédard AC, Schulz KP, Krone B, Pedraza J, Duhoux S, Halperin JM, Newcorn JH. Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study. Psychiatry Res. 2015 Mar 30;231(3):353-6. doi: 10.1016/j.pscychresns.2015.01.012. Epub 2015 Jan 19.</citation>
    <PMID>25659477</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2012</study_first_submitted>
  <study_first_submitted_qc>October 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2012</study_first_posted>
  <results_first_submitted>March 29, 2017</results_first_submitted>
  <results_first_submitted_qc>January 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2018</results_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Jeffrey Newcorn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Intuniv</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Guanfacine Hydrochloride XR</title>
          <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Flexible dose titration of placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data unavailable for one participant in each group.</population>
      <group_list>
        <group group_id="B1">
          <title>Guanfacine Hydrochloride XR</title>
          <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Flexible dose titration of placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" spread="1.7"/>
                    <measurement group_id="B2" value="11.5" spread="2.5"/>
                    <measurement group_id="B3" value="11.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Full Scale IQ</title>
          <description>Full Scale IQ - People who score generally between 70 and 130 are considered to be within the normal range of IQ functioning, where 100 is the theoretical average. Those scoring 130 and above have significantly greater cognitive resources than the average population, and those scoring 70 and below population have significantly fewer cognitive resources.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110.0" spread="21.6"/>
                    <measurement group_id="B2" value="101.8" spread="13.1"/>
                    <measurement group_id="B3" value="105.7" spread="17.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Attention-Deficit/Hyperactivity Disorder (ADHD) subtype</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Combined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inattentive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbid Oppositional Defiant Disorder (ODD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions – Severity scale (CGI-S)</title>
          <description>Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's symptoms at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of symptoms at the time of rating 1, normal, not at all ill; 2, minimally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, very servely ill.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="1.0"/>
                    <measurement group_id="B2" value="5.4" spread="0.9"/>
                    <measurement group_id="B3" value="5.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior stimulant treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Go/No-go Task Performance Correct Inhibitions</title>
        <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Go/No-go Task Performance Correct Inhibitions</title>
          <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
          <units>percentage correct inhibitions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Correct inhibitions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="8"/>
                    <measurement group_id="O2" value="89" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks Correct inhibitions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="6"/>
                    <measurement group_id="O2" value="92" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Go/No-go Task Reaction Time</title>
        <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Go/No-go Task Reaction Time</title>
          <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Reaction time (RT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="572" spread="144"/>
                    <measurement group_id="O2" value="543" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Reaction time standard deviation (RTSD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" spread="109"/>
                    <measurement group_id="O2" value="165" spread="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks Reaction time (RT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="562" spread="106"/>
                    <measurement group_id="O2" value="550" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks Reaction time standard deviation (RTSD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184" spread="93"/>
                    <measurement group_id="O2" value="166" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions (CGI-I)</title>
        <description>Clinical response was the Clinical Global Impression-Improvement scale (CGI-I). Lower CGI-I scores indicate greater improvement (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.)</description>
        <time_frame>up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions (CGI-I)</title>
          <description>Clinical response was the Clinical Global Impression-Improvement scale (CGI-I). Lower CGI-I scores indicate greater improvement (1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6= much worse; 7=very much worse.)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.7"/>
                    <measurement group_id="O2" value="2.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Atomoxetine Stimulant Side Effects Rating Scale (ASSERS)</title>
        <description>Side effects rating scale. Assesses side effects known to occur in prior research using stimulant and non stimulant medications for treatment of ADHD. Scores range from 0 (not present) to 9 (severe side effects) and have been reported in aggregate as sum of severity responses on highest dose. This number is the sum of ASSERS, meaning it is the number and severity of side effects experienced. The percentage change in score from baseline.</description>
        <time_frame>up to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Atomoxetine Stimulant Side Effects Rating Scale (ASSERS)</title>
          <description>Side effects rating scale. Assesses side effects known to occur in prior research using stimulant and non stimulant medications for treatment of ADHD. Scores range from 0 (not present) to 9 (severe side effects) and have been reported in aggregate as sum of severity responses on highest dose. This number is the sum of ASSERS, meaning it is the number and severity of side effects experienced. The percentage change in score from baseline.</description>
          <units>percentage of mean effects improvement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="65.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Finger Windows</title>
        <description>Neuropsychological assessment: Finger Windows - a measure of spatial working memory. The participant shows memory of a demonstrated visual pattern. The examiner models a given sequence of windows and ask the participant to imitate the sequence by placing their finger through the same windows in the correct order. The total number of correct sequences achieved determines the level of performance.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Finger Windows</title>
          <description>Neuropsychological assessment: Finger Windows - a measure of spatial working memory. The participant shows memory of a demonstrated visual pattern. The examiner models a given sequence of windows and ask the participant to imitate the sequence by placing their finger through the same windows in the correct order. The total number of correct sequences achieved determines the level of performance.</description>
          <units>correct sequences</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Finger Windows - F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="6.52"/>
                    <measurement group_id="O2" value="10.75" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finger Windows -B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.35" spread="5.45"/>
                    <measurement group_id="O2" value="8.00" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Digit Span</title>
        <description>Neuropsychological assessment - Digit Span. The Digit Span test is either conducted verbally or using a computer program. A sequence of numbers is shown or read out to the participant. The participant is then told to repeat the numbers that were shown or read to them. This process continues until the participant can no longer remember either the full sequence of numbers or the correct order. This sequence is also continued until the participant makes an error. The Digit Span test is scored by the amount of numbers the participant was able to remember in each test. The scorer must add the total number of correct sequences, backwards and forwards. This test is also scored differently for a range of ages.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Digit Span</title>
          <description>Neuropsychological assessment - Digit Span. The Digit Span test is either conducted verbally or using a computer program. A sequence of numbers is shown or read out to the participant. The participant is then told to repeat the numbers that were shown or read to them. This process continues until the participant can no longer remember either the full sequence of numbers or the correct order. This sequence is also continued until the participant makes an error. The Digit Span test is scored by the amount of numbers the participant was able to remember in each test. The scorer must add the total number of correct sequences, backwards and forwards. This test is also scored differently for a range of ages.</description>
          <units>correct sequences</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Digit Span - F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="1.73"/>
                    <measurement group_id="O2" value="7.54" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digit Span - B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.62" spread="8.76"/>
                    <measurement group_id="O2" value="48.62" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Attention Deficit Hyperactivity Disorder Rating Scale IV (ADHDRS IV)</title>
        <description>Norm referenced parent interview to assess severity and frequency of ADHD symptoms. Scores are reported as sums 0 (no symptoms) to 54 (severe).</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Attention Deficit Hyperactivity Disorder Rating Scale IV (ADHDRS IV)</title>
          <description>Norm referenced parent interview to assess severity and frequency of ADHD symptoms. Scores are reported as sums 0 (no symptoms) to 54 (severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.67" spread="9.01"/>
                    <measurement group_id="O2" value="39.15" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="6.96"/>
                    <measurement group_id="O2" value="22.69" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Performance Test - Commissions</title>
        <description>Neuropsychological assessment - Continuous Performance Test - Commissions. CPT is a task-oriented computerized assessment of attention-related problems. Scores are compared with the normative scores for the age, group and gender of the person being tested. A t-score of 50 is equal to the mean, with higher values indicating more problematic behaviors and lower scores indicating less problematic behaviors.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Performance Test - Commissions</title>
          <description>Neuropsychological assessment - Continuous Performance Test - Commissions. CPT is a task-oriented computerized assessment of attention-related problems. Scores are compared with the normative scores for the age, group and gender of the person being tested. A t-score of 50 is equal to the mean, with higher values indicating more problematic behaviors and lower scores indicating less problematic behaviors.</description>
          <units>t-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.62" spread="3.81"/>
                    <measurement group_id="O2" value="46.99" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Go/No-go Task Performance Correct Responses</title>
        <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Guanfacine Hydrochloride XR</title>
            <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Flexible dose titration of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Go/No-go Task Performance Correct Responses</title>
          <description>Measures of go/no-go task performance during functional magnetic resonance imaging. Performance on a go-nogo task inside the scanner.</description>
          <units>percentage correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Correct responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="18"/>
                    <measurement group_id="O2" value="75" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks Correct responses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" spread="15"/>
                    <measurement group_id="O2" value="74" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Guanfacine Hydrochloride XR</title>
          <description>Flexible dose titration of guanfacine extended release - titrated in doses from 1 - 4 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Flexible dose titration of placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>ASSERS</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Difficulty Sleeping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness upon standing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Appearing sedated</sub_title>
                <description>could not tolerate dose rise, dose reduced</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <description>subjective feeling of weakness, without loss of strength.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Infection</sub_title>
                <description>Sore throat and nasal congestions secondary to common cold</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Increased Anxiety/Panic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Irritable and Moody</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small sample size in this pilot study limited power to detect large-sized effects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Department of Psychiatry</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-6623</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

